艾洛-HSCT接种者的COVID-19疫苗反应:来自现实世界前性队列研究的见解
Emine Merve Savaş1, Şeyma Yıldız1, Zübeyde Nur Özkurt1
1Department of Hematology, Faculty of Medicine, Gazi University, Ankara 06560, Türkiye.
Vaccines
|July 30, 2025
概括
对于全源造血干细胞移植 (Allo-HSCT) 接受者来说,COVID-19 疫苗接种是安全有效的,在三次或更多剂量后观察到的抗体反应较高. 某些药物和低免疫球蛋白水平可能会降低疫苗在这个脆弱群体中的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
- 传染性疾病 传染性疾病
背景情况:
- 全源造血干细胞移植 (Allo-HSCT) 接受者面临严重COVID-19的风险增加.
- 疫苗接种对于这种免疫力低下的人群来说是一个关键的预防措施.
- 在Allo-HSCT接种者中,关于COVID-19疫苗有效性的现实数据至关重要.
研究的目的:
- 评估Allo-HSCT接种者对COVID-19疫苗的免疫反应.
- 为了评估临床结果,包括不良事件和感染,疫苗接种后.
- 在这个队列中确定影响抗体对接种反应的因素.
主要方法:
- 对95名接种了BNT162b2或CoronaVac.疫苗的Allo-HSCT接种者的前性队列研究.
- 通过化学发光微粒免疫测试对抗SARS-CoV-2尖端蛋白抗体的定量测量.
- 对患者和疫苗相关因素,不良事件 (GVHD,感染) 和血清免疫球蛋白水平的分析.
主要成果:
- 86.3%的Allo-HSCT接种者在接种疫苗后获得了足够的抗体反应.
- ≥3个疫苗剂量与显著更高的抗体标位相关 (OR:0.11;95%CI:0.02-0.53;p=0.006).
- 卢克索利提尼布/伊布鲁丁尼布使用 (OR:38.39;95% CI:3.14-468.95;p=0.004) 和低血糖球蛋白血症 (OR:0.17;95% CI:0.03-0.96;p=0.045) 与抗体反应减少有关.
结论:
- 在Allo-HSCT接种者中,COVID-19疫苗的安全性和有效性得到了证明.
- 在≥3剂疫苗接种后观察到增强的免疫反应.
- 针对性疫苗接种策略和监测对于接受特定治疗或患有低血糖球蛋白血症的患者至关重要.
更多相关视频
10:01Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015
7.8K
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
14.5K
相关概念视频
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
